Abstract T P102: Outcomes of Tailored Angioplasty for Symptomatic Intracranial Atherosclerosis: A Prospective Cohort Study after Sammpris
Background and Purpose: High periprocedural complication rate is a key limitation of endovascular treatment of intracranial atherosclerotic disease (ICAD) despite potential risk reduction of recurrent stroke. Based on the SAMMPRIS trial, with modification of the target population and tailored angioplasty, we prospectively evaluated efficacy and safety of a novel endovascular approach for patients with ICAD.
Methods: From November 2011 to October 2012, 156 patients were consecutively recruited into a prospective single-center study. Patients were divided into 3 groups based on 4 angioplasty methods: Apollo (A) Group, Gateway/Gateway+Stent (G-GS) group, and Gateway+Wingspan (GW) Group. The primary endpoints were successful procedure rate and any vascular event within 30 days.
Results: Overall technical success rate was 96.8% (151/156). Intracranial stenting was successful in 97.6% of patients in group A and only 91.2% in group G-GS with no significant differences between three groups (p=0.213). The 30-day composite stroke or death rate was 4.5% (7/156). Stroke occurred in 4 patients of group A and in 3 patients of group GW. 140 (89.7%) patients had no any neurological deficit and no patient died during 30-day follow-up.
Conclusions: Individual treatment of ICAD using tailored devices according to lesion morphology was feasible and safe in patients with limited collateral circulation.
Author Disclosures: M. Zhongrong: None. S. Ligang: None. L. David S.: None. L. Liping: None. M. Ning: None. W. Xianwei: None. W. Yilong: None. M. Dapeng: None. G. Feng: None. Z. Xingquan: None. D. Kehui: None. Z. Dong: None. G. peiyi: None.
- © 2014 by American Heart Association, Inc.